GUANGDONG TAIANTANG PHARMACEUTICAL CO., LTD. Financials Guangdong Taiantang Pharmaceutical Co., Ltd.
Equities
002433
CNE100000Q92
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.51 CNY | -5.56% |
|
-22.73% | -78.48% |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6,505 | 3,596 | 3,519 | 3,182 | 5,720 | 3,351 |
| Enterprise Value (EV) 1 | 8,597 | 5,603 | 5,537 | 5,556 | 7,172 | 4,678 |
| P/E ratio | 26.4 x | 13.4 x | 35.3 x | 138 x | -7.1 x | -4.08 x |
| Yield | - | 1.51% | 0.33% | - | - | - |
| Capitalization / Revenue | 2.01 x | 1.08 x | 0.88 x | 0.89 x | 2.53 x | 4.62 x |
| EV / Revenue | 2.65 x | 1.69 x | 1.38 x | 1.55 x | 3.17 x | 6.45 x |
| EV / EBITDA | 18.3 x | 20.8 x | 20.6 x | 25.7 x | -79.5 x | -8.93 x |
| EV / FCF | -11.1 x | 76.3 x | 15.1 x | -9.84 x | -397 x | 8.85 x |
| FCF Yield | -9% | 1.31% | 6.63% | -10.2% | -0.25% | 11.3% |
| Price to Book | 1.33 x | 0.69 x | 0.67 x | 0.61 x | 1.29 x | 0.93 x |
| Nbr of stocks (in thousands) | 768,955 | 766,773 | 766,773 | 766,773 | 766,773 | 766,773 |
| Reference price 2 | 8.460 | 4.690 | 4.590 | 4.150 | 7.460 | 4.370 |
| Announcement Date | 4/10/18 | 4/9/19 | 4/24/20 | 4/9/21 | 6/15/22 | 4/28/23 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 3,239 | 3,315 | 4,013 | 3,582 | 2,264 | 724.8 |
| EBITDA 1 | 470.2 | 268.8 | 268.4 | 216.5 | -90.26 | -524 |
| EBIT 1 | 396.2 | 187.8 | 175.7 | 114.5 | -189.2 | -624.3 |
| Operating Margin | 12.23% | 5.67% | 4.38% | 3.2% | -8.35% | -86.12% |
| Earnings before Tax (EBT) 1 | 354.2 | 328.6 | 124.1 | 38.04 | -842.2 | -820.3 |
| Net income 1 | 290.4 | 270.9 | 96.09 | 22.23 | -803.3 | -822.8 |
| Net margin | 8.97% | 8.17% | 2.39% | 0.62% | -35.48% | -113.52% |
| EPS 2 | 0.3200 | 0.3500 | 0.1300 | 0.0300 | -1.050 | -1.070 |
| Free Cash Flow 1 | -774 | 73.46 | 367.1 | -564.6 | -18.07 | 528.7 |
| FCF margin | -23.9% | 2.22% | 9.15% | -15.76% | -0.8% | 72.94% |
| FCF Conversion (EBITDA) | - | 27.33% | 136.81% | - | - | - |
| FCF Conversion (Net income) | - | 27.12% | 382.06% | - | - | - |
| Dividend per Share | - | 0.0707 | 0.0151 | - | - | - |
| Announcement Date | 4/10/18 | 4/9/19 | 4/24/20 | 4/9/21 | 6/15/22 | 4/28/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 2,092 | 2,007 | 2,017 | 2,374 | 1,452 | 1,327 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 4.448 x | 7.465 x | 7.517 x | 10.97 x | -16.08 x | -2.532 x |
| Free Cash Flow 1 | -774 | 73.5 | 367 | -565 | -18.1 | 529 |
| ROE (net income / shareholders' equity) | 6.03% | 5.32% | 1.9% | 0.5% | -16.6% | -20.5% |
| ROA (Net income/ Total Assets) | 3.29% | 1.4% | 1.26% | 0.8% | -1.42% | -5.5% |
| Assets 1 | 8,815 | 19,417 | 7,650 | 2,778 | 56,762 | 14,964 |
| Book Value Per Share 2 | 6.350 | 6.770 | 6.820 | 6.830 | 5.780 | 4.710 |
| Cash Flow per Share 2 | 0.3900 | 0.5200 | 0.3600 | 0.2700 | 0.1000 | 0.0600 |
| Capex 1 | 673 | 190 | 120 | 145 | 25.7 | 3.22 |
| Capex / Sales | 20.77% | 5.75% | 3% | 4.04% | 1.13% | 0.44% |
| Announcement Date | 4/10/18 | 4/9/19 | 4/24/20 | 4/9/21 | 6/15/22 | 4/28/23 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -78.48% | 54.01M | |
| +37.08% | 6.01B | |
| -17.43% | 4.4B | |
| -9.46% | 3.17B | |
| +0.51% | 3.07B | |
| -3.53% | 2.51B | |
| +41.15% | 1.88B | |
| -5.15% | 1.73B | |
| +0.09% | 1.65B | |
| -10.38% | 1.58B |
- Stock Market
- Equities
- 002433 Stock
- Financials Guangdong Taiantang Pharmaceutical Co., Ltd.
